The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
BUSINESS
Olmetec Sales Nosedive 67.8% in North America in FY2017: Daiichi Sankyo
Daiichi Sankyo suffered a hefty sales plunge of its major hypertension drug Olmetec (olmesartan), particularly in the US, with its FY2017 group revenue up only 0.5% to 960 billion yen, which actually translates into a year-on-year decline of 8.9 billion…
To read the full story
Related Article
- Daiichi Sankyo Reels from Olmesartan LOE, Logs 3.2% Sales Fall
April 26, 2019
- Daiichi Sankyo’s Half-Year Revenue Fell 4.8% as Generics Sap Olmesartan Sales
November 1, 2018
- Takeda’s Takeover Bid for Shire “Thought-Provoking”: Daiichi Sankyo CEO
May 1, 2018
- Despite Upbeat AGs, Daiichi Sankyo to Closely Watch Pricing Environment: CEO
May 1, 2018
- Daiichi Sankyo to Announce “Important Measures” to Shore Up Biz by 2nd Qtr Earnings
May 1, 2018
- Daiichi Sankyo Ekes Out 2.5% Sales Rise despite Olmetec LOE, Operating Profit Sags 33.5%
November 1, 2017
- Daiichi Sankyo Eclipses Takeda, Becomes Top Maker by Japan Ethical Drug Sales
May 12, 2017
BUSINESS
- Kissei to Run Additional PIII for Spinocerebellar Degeneration Drug
March 17, 2025
- Novel β-Lactamase Inhibitor Nacubactam Safe and Effective: Meiji
March 17, 2025
- AbbVie Files Migraine Med Atogepant in Japan
March 17, 2025
- Zeria’s Hyperkalemia Drug Veltassa Now Available in Japan
March 17, 2025
- Jiho Survey Finds Improvement in Price Revision Rates for Generic Players
March 17, 2025
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…